"Overseas Market Strategy" Neurophet Supplies 'Neurophet Scale PET' to Singapore

[Financial News] Neurophet announced on the 20th that it has signed a supply contract for 'Neurophet Scale PET' with the National University of Singapore and a general hospital.
Neurophet plans to verify the clinical utility of product analysis technology and promote technology commercialization by utilizing the PET imaging and brain MRI data owned by both institutions.
Neurophet Scale PET is software that quantitatively analyzes biomarkers marked with radioactive tracers using PET imaging and MRI. It targets various biomarkers such as △amyloid beta and tau protein, which are Alzheimer's disease biomarkers △fluorodeoxyglucose (FDG) △dopamine. It automatically provides the standardized uptake value ratio (SUVR), which is the standardized ratio of the uptake amount in the remaining areas based on the uptake amount of tissues with a certain metabolic rate.
Jun-Gil Bin, co-CEO of Neurophet, said, "Through this supply, we have gained an opportunity to prove the reliability and clinical utility of the technology," and "We plan to accelerate our entry into the Southeast Asian market."
kaya@fnnews.com Hye-Rim Choi Reporter